Related Experiment Videos
Progress in rheumatology: understanding autoimmune disease
1Division of Arthritis and Rheumatic Diseases, Oregon Health Sciences University, Portland, USA.
Geriatrics
|January 1, 1996
Summary
Wegener's granulomatosis is now a treatable condition, with a 93% remission rate. Advances in classification, diagnostics, and cyclophosphamide treatment have transformed patient survival for this rheumatologic disorder.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Wegener's granulomatosis was historically a fatal condition diagnosed posthumously.
- Significant advancements in understanding and managing this vasculitis have occurred over the last 50 years.
Observation:
- The prognosis for Wegener's granulomatosis has dramatically improved.
- Current survival rates are high, with a reported 93% complete remission rate at 4 years post-diagnosis.
Findings:
- Four key medical advances have transformed patient outcomes.
- These include a structured classification of vasculitides, development of specific serologic assays, effective cyclophosphamide treatment, and new etiological insights.
Implications:
- These advances have shifted Wegener's granulomatosis from a uniformly fatal disease to a manageable condition.
- Improved diagnostics and targeted therapies offer better long-term prognoses for affected individuals.